

12/02/2021

Dear Requester,

Thank you for your Freedom of Information request.

In accordance with S.1 (1) (a) of the Freedom of Information Act 2000 (FOIA), I can confirm that we do hold the information relevant to your request. 315

**You asked:**

**Response from Luton and Dunstable University Hospital**

I am researching the incidence and treatment of Myelofibrosis and Oesophageal cancer. Could you please answer the following questions for patients treated by your trust:

Q1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?

- Advanced oesophageal cancer - **Yes**
- Myelofibrosis - **Yes**

Q2. Please provide the total number of patients treated in the last 6 months for:

- Myelofibrosis **between 0 & 5**
- Myelofibrosis – patients over the age 65 **between 0 & 5**
- Oesophageal cancer (any type) **25**
- Oesophageal adenocarcinoma **between 0 & 10**
- Oesophageal squamous cell carcinoma **between 0 & 5**
- Unresectable Oesophageal squamous cell carcinoma **between 0 & 5**

Q3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with: - **This data is not held**

- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with; **This data is not held**

- Ruxolitinib
- Hydroxyurea
- Watch and wait approach

Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

**No oesophageal trials running at the moment at the L&D**

## Response from Bedford Hospital

Q1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?

- Advanced oesophageal cancer
- Myelofibrosis

**Yes**

Q2. Please provide the total number of patients treated in the last 6 months for:

- Myelofibrosis **0**
- Myelofibrosis – patients over the age 65 **0**
- Oesophageal cancer (any type) **21**
- Oesophageal adenocarcinoma **15**
- Oesophageal squamous cell carcinoma **between 0 & 5**
- Unresectable Oesophageal squamous cell carcinoma **0**

Q3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with:

- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) **between 0 & 5**
- Any other systemic anti-cancer therapy **0**
- Palliative care only **between 0 & 5**

Q4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with;

- Ruxolitinib **between 0 & 5**
- Hydroxyurea **between 0 & 10**
- Watch and wait approach **not known**

Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

**No**

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

**No**

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF [www.ico.org.uk](http://www.ico.org.uk)

Yours sincerely,

*IG/FOI Coordinator*

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this

information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to: [dataprotectionofficer@ldh.nhs.uk](mailto:dataprotectionofficer@ldh.nhs.uk)